If things are so obvious, how Geron management still could get all the info and data for FDA? Five months already passed since the holding started.
Atossa intends to submit the information and data to the FDA on or before August 20, 2014. So, this should be done or nearly done. If it takes 30days for FDA to review the data. then we should see the results by early Oct.
Something is coming. If relaunch the device, we would see $5 again. Depends on if FDA gives clearance or not. As least the company said they are working toward that goal.
You should phrase like that: eBay screws the BAD sellers yet again. oh yeah, good move. Think that if buyers are hesitating, Will you see any transactions?
Apparently, the problem is the management. They should have better communications with the investment community so that more people can recognize its value. The company is not doing anything even after the panel meeting (surprisingly). Secondly, the company's way of raising cash is kind of stupidest. Whoever will use ATM to raise cash if getting better way to do it? Not any investment institution will put any long time money in if the company keeps selling stock on the market. (ATM). At least, this company needs a better IR department.
How can one CEO handle two completely businesses well simultaneously?
The last two years just showed that while paypal is growing well but e-auction stayed behind.
Paypal has to go alone and let it grow faster, not under the hood of EBAY.
No offense, just tell the truth.
QQQ went from $50s from 2013 to $98 and EBAY stays negative for the same time period. Something must be wrong, period.
CEO and his team runs out of tricks. The last rabbit was pulled out and no more left. So BOD should search for a new leader for the company.
If you check the background of CEO, it is easy to know what style the CEO is and how he built his empire. It is way overdue to refresh the leadership. Wish this is not too long time waiting.
If CEO keeps doing this. SO much under-performing the market. Something must be done to remove the CEO.
Finally, someone gets similar opinion like I just posted yesterday.
IMHO, the management is more looks like lack expertise in handling such cancer drugs. The evidence is they just forced out the SV of Dev. And temporarily appointed another one who might do not have the expertise either. Therefore, it get Dr. T in. Eventually, Dr. T might overlook all the drugs unless the company finds another one who qualifies the job.
Another which also obvious is that CEO does not qualify either. Otherwise, how could he appoint the former SV Dev. and trial was not properly designed in case of adverse effects exits such data should be collected immediately.
Looks like Dr.T comes for rescue but eventually current top executives should be replaced in order to get the drugs through FDA approval.